Vinny Cassano is a contributor at BioMedReports and authors the popular blog VFC's Stock House here he shares his thoughts wiith us on CVM.
The saga of Cel Sci continues, but I couldn't resist adding shares at eighty seven cents on Monday as the stock continued to slide. No news has been released to justify the recent price action, yet with so much possible news pending over the short to mid term, I couldn't help but add to my position of the stock near the low of the day.
----------------------------------------------------------------------
Sign-up for Free to Receive Future Commentary
and Trading Alerts on CVM
----------------------------------------------------------------------
Over the years I have accumulated CVM with strictly a long term outlook, but the lower the stock slides, then it becomes a decent short term play as well.
According to an article about BiCryst's Peramavir released on Monday, officials at Cel Sci will release an update on the H1N1 LEAPS program "very soon", and many longs of the stock have been 'long' awaiting an update. There are impatient investors out there who want to see the company respond to the day to day action of the stock price, but I'm the type that doesn't believe should issue news unless it's 'quality' news; meaning no fluff.
Remember, earlier this year I thought that Cel Sci was issuing some 'fluff' with the early swine flu PRs, but the one PR that indicated that the FDA had cleared the company to conduct some initial testing is the one that validated the 'LEAPS to potentially treat H1N1' platform, in my opinion.
Additional news that should be released within the next couple of months regarding Cel Sci is the validation of the Baltimore area facility and the commencement of the Multikine Phase III trial.
It's tough to predict day to day price action in a stock that is being played such as CVM, but I'm sure of one thing - the lower this one goes, then the more that I will buy.
My ultimate horizon for investing in CVM is for the long term - to see how Multikine plays out - but there's enough potential news that could hit the wires over the short term that the impatient investor could also be quickly satisfied.
Disclosure: Long CVM.
